 CAMBRIDGE, Mass. SALISBURY, England--BUSINESS WIRE--KalVista Pharmaceuticals, Inc. NASDAQ: KALV, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today the appointment of Paul K. Audhya, MD, MBA, as Chief Medical Officer. As we advance our oral hereditary angioedema franchise in the clinic, KalVista will be strategically growing by adding individuals with deep experience in late-stage dru 